Introduction {#s1}
============

Acute myocardial infarction (AMI), including both ST segment elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), represent a major cause of morbidity and mortality worldwide \[[@R01]\]. Although healthcare systems have made marked improvements in developing systematic methods for early recognition and management of patients with AMI, short-term in-hospital mortality remains high.

Several studies in the USA and Europe have investigated the predictors of in-hospital mortality post-AMI \[[@R02]-[@R07]\]. Several variables were identified related to the clinical characteristics of the patients and their comorbidities \[[@R03], [@R04], [@R07]-[@R10]\]. Similar studies on AMI patients in developing countries are scarce \[[@R11]\], and little is known about the management and mortality rates of such patients in these countries \[[@R12]\]. The aim of our study is to investigate the predictors for in-hospital mortality in patients admitted with AMI at the American University of Beirut Medical Center (AUBMC), a tertiary referral university hospital in Lebanon.

Patients and Methods {#s2}
====================

This is a substudy of a large retrospective study that enrolled all patients (1,025) admitted with an acute coronary syndrome to AUBMC between January 1, 2002 and December 30, 2005 \[[@R13]\]. In this substudy, we focus on the subgroup of patients who had AMI (either STEMI or NSTEMI) with the appropriate clinical presentation, electrocardiograph (ECG) findings and rise in cardiac biomarkers as per published guidelines \[[@R14]\]. AUBMC is the largest tertiary referral university hospital in Lebanon with a 20 bed coronary care unit, two active cardiac catheterization laboratories and a busy cardiothoracic surgery program.

The clinical characteristics of patients as well as the occurrence of in-hospital death were collected retrospectively from medical chart review. Statistical analysis was performed using the Statistical Package for Social Sciences software (SPSS version 15). Continuous variables are presented as mean ± SD and categorical variables are presented as frequencies and percentages. Comparison of baseline characteristics and in-hospital interventions and outcomes among the three groups of patients (All AMI, STEMI and NSTEMI) in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, were done using the analysis of variance (ANOVA) test (for continuous variables) or the χ^2^ homogeneity test (for categorical variables). Logistic regression analysis was performed to determine the predictors of in-hospital mortality among the three groups.

###### Clinical Characteristic of the Study Population

                              Total sample   All Patients   STEMI       NSTEMI                                                                  
  --------------------------- -------------- -------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -------
  Demographic                 Mean age       63 ± 13        77 ± 12     \< 0.0001   59 ± 13     77 ± 12     \< 0.0001   66 ± 13     76 ± 12     0.001
  Age \> 65 years             216 (47%)      32 (82%)       \< 0.0001   79 (38%)    14 (78%)    0.001       137 (54%)   18 (86%)    0.005       
  Female gender               104 (22%)      15 (39%)       0.02        34 (16%)    5 (28%)     0.20        70 (28%)    10 (48%)    0.05        
  Cardiac risk factors        Hypertension   234 (50%)      20 (51%)    0.92        77 (37%)    8 (44%)     0.51        157 (62%)   12 (57%)    0.67
  Diabetes                    142 (31%)      17 (44%)       0.09        48 (23%)    5 (28%)     0.58        94 (37%)    12 (57%)    0.07        
  Hyperlipidemia              204 (44%)      13 (33%)       0.20        83 (40%)    3 (17%)     0.06        121 (48%)   10 (48%)    1.00        
  Previous cardiac diseases   h/o CAD        169 (36%)      22 (56%)    0.01        45 (21%)    8 (44%)     0.04        124 (49%)   14 (67%)    0.12
  h/o MI                      54 (12%)       8 (21%)        0.13        13 (6%)     3 (17%)     0.12        41 (16%)    5 (24%)     0.36        
  CHF                         41 (9%)        12 (31%)       \< 0.0001   3 (1%)      4 (22%)     0.001       38 (15%)    8 (38%)     0.01        
  Previous intervention       Angioplasty    34 (7%)        3 (8%)      1.00        14 (7%)     1 (6%)      1.00        20 (8%)     2 (9.5%)    0.68
  CABG                        68 (15%)       12 (31%)       0.008       15 (7%)     3 (17%)     0.16        53 (21%)    9 (43%)     0.03        
  Comorbidities               COPD           21 (4.5%)      4 (10%)     0.12        4 (2%)      2 (11%)     0.07        17 (7%)     2 (9.5%)    0.65
  CKD                         43 (9%)        11 (28%)       0.001       4 (2%)      3 (17%)     0.01        39 (15%)    8 (38%)     0.01        
  Stroke                      15 (3%)        7 (18%)        0.001       5 (2%)      4 (22%)     0.003       10 (4%)     3 (14%)     0.07        
  PVD                         22 (5%)        5 (13%)        0.05        4 (2%)      1 (6%)      0.34        18 (7%)     4 (19%)     0.07        
  Admission features          Sinus rhythm   427 (92%)      34 (87%)    0.36        201 (96%)   16 (89%)    0.21        226 (89%)   18 (86%)    0.72
  A-Fib                       24 (5%)        2 (5%)         1.00        5 (2%)      0(0%)       1.00        19 (7.5%)   2 (9.5%)    0.67        
  AV block                    3 (0.6%)       1 (3%)         0.28        1 (0.5%)    0 (0%)      1.00        2 (0.8%)    1 (5%)      0.21        
  SBP (mm Hg)                 136 ± 29       120 ± 27       0.001       133 ± 29    118 ± 32    0.04        138 ± 28    123 ± 21    0.01        
  HR                          84 ± 22        90 ± 17        0.12        81 ± 21     91 ± 15     0.04        87 ± 23     89 ± 18     0.72        
  Cr \> 2 mg/dL               29 (6%)        9 (23%)        0.001       5 (2%)      4 (22%)     0.003       24 (9%)     5 (24%)     0.04        
  Hb (g/dL)                   13 ± 2         12 ± 2         0.001       14 ± 2      13 ± 2      0.05        13 ± 2      11 ± 2      0.008       
  Heart failure               40 (9%)        14 (36%)       \< 0.0001   11 (5%)     6 (33%)     0.001       29 (11%)    8 (38%)     0.003       
  Cardiogenic shock           8 (2%)         4 (10%)        0.01        6 (3%)      4 (22%)     0.004       2 (0.8%)    0 (0%)      1.00        
  Anterior MI                 132 (28%)      15 (39%)       0.09        88 (42%)    12 (67%)    0.23        44 (17%)    3 (14%)     0.19        
  2 vessel CAD                153 (35%)      6 (18%)        0.007       74 (37%)    2 (13%)     0.02        79 (33%)    4 (22%)     0.19        
  EF (%)                      48 ± 14        28 ± 11        \< 0.0001   49 ± 12     29 ± 11     \< 0.0001   48 ± 15     28 ± 12     \< 0.0001   

CAD: coronary artery disease; MI: myocardial infarction; CHF: congestive heart failure; CABG: coronary artery bypass graft; CKD: chronic kidney disease; PVD: peripheral vascular disease; A-Fib: atrial fibrillation; AV block: atrioventricular block; SBP: systolic blood pressure; HR: heart rate; Hb: hemoglobin; EF: ejection fraction.

###### In-Hospital Utilization of Medications and Interventions

                             Total sample   All patients   STEMI       NSTEMI                                                                  
  -------------------------- -------------- -------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ------
  In-hospital drugs          Aspirin        433 (93%)      31 (80%)    0.006       202 (96%)   13 (72%)    0.002       231 (91%)   18 (86%)    0.43
  Clopidogrel                382 (82%)      19 (49%)       \< 0.0001   174 (83%)   6 (33%)     \< 0.0001   208 (82%)   13 (62%)    0.04        
  Beta blocker               289 (62%)      11 (28%)       \< 0.0001   136 (65%)   2 (11%)     \< 0.0001   153 (60%)   9 (43%)     0.12        
  CCB                        37 (8%)        5 (13%)        0.36        4 (2%)      1 (6%)      0.34        33 (13%)    4 (19%)     0.50        
  Statin                     282 (61%)      5 (13%)        \< 0.0001   142 (68%)   0 (0%)      \< 0.0001   140 (55%)   5 (24%)     0.006       
  ACEI                       202 (44%)      17 (44%)       0.10        97 (46%)    6 (33%)     0.29        105 (41%)   11 (52%)    0.33        
  ARB                        52 (11%)       3 (8%)         0.79        14 (7%)     0 (0%)      0.61        38 (15%)    3 (14%)     1.00        
  Heparin                    336 (72%)      24 (62%)       0.15        164 (78%)   11 (61%)    0.14        172 (68%)   13 (62%)    0.59        
  LMWH                       174 (38%)      17 (44%)       0.45        66 (31%)    5 (28%)     0.75        108 (43%)   12 (57%)    0.19        
  GPIIb/IIIa                 113 (24%)      3 (8%)         0.02        40 (19%)    1 (6%)      0.21        73 (29%)    2 (9.5%)    0.06        
  Dopamine                   24 (5%)        20 (51%)       \< 0.0001   9 (4%)      7 (39%)     \< 0.0001   15 (6%)     13 (62%)    \< 0.0001   
  Dobutamine                 57 (12%)       25 (64%)       \< 0.0001   26 (12%)    11 (61%)    \< 0.0001   31 (12%)    14 (67%)    \< 0.0001   
  Amiodarone                 83 (18%)       12 (31%)       0.05        30 (14%)    4 (22%)     0.32        53 (21%)    8 (38%)     0.10        
  In-hospital intervention   Thrombolytic   132 (28%)      2 (5%)      0.002       131 (62%)   2 (11%)     \< 0.0001   \-          \-          \-
  Angioplasty                166 (38%)      4 (12%)        0.003       101 (51%)   3 (20%)     0.02        65 (27%)    1 (6%)      0.05        
  CABG                       86 (20%)       6 (18%)        0.84        41 (21%)    3 (20%)     1.00        45 (19%)    3 (17%)     1.00        
  Pace maker                 7 (1.5%)       0 (0%)         1.00        4 (2%)      0 (0%)      1.00        3 (1%)      0 (0%)      1.00        
  IABP                       6 (1%)         2 (5%)         0.12        4 (2%)      2 (11%)     0.07        2 (0.8%)    0 (0%)      1.00        

CCB: calcium channel blocker; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; LMWH: low molecular weight heparin; GPIIb/IIIa: glycoprotein IIb/IIIa inhibitor; CABG: coronary artery bypass graft; IABP: intra-aortic balloon pump.

Results {#s3}
=======

The clinical characteristics of the study population as well as the medications and interventions utilized are shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The study included a total of 503 AMI patients (45% STEMI and 55% NSTEMI). The overall in-hospital mortality was 7.8% (7.9% in STEMI and 7.6% in NSTEMI).

In the total group of AMI patients, those who died were older (mean age of 77 ± 12 years versus 63 ± 13 years, P \< 0.0001), had a higher percentage of women (39% versus 22%, P = 0.02) and a higher prevalence of prior coronary artery disease (CAD) (56% versus 36%, P = 0.01), congestive heart failure (CHF) (31% versus 9%, P \< 0.0001), chronic kidney disease (CKD) (28% versus 9%, P \< 0.001) and stroke (18% versus 3%, P \< 0.001). They also had a lower mean systolic blood pressure on admission (120 ± 27 mm Hg versus 136 ± 29 mm Hg, P = 0.001), hemoglobin level (12 ± 2 g/dL versus 13 ± 2 g/dL, P = 0.001) and ejection fraction (28 ± 11% versus 48 ± 14%, P \< 0.0001). In addition, they had a higher prevalence of decompensated heart failure on admission (36% versus 9%, P \< 0.0001) and cardiogenic shock (10% versus 2%, P = 0.01). In terms of medical therapy, patients who died were more likely to be on inotropic support with dopamine or dobutamine, but they were less likely to receive other medications such as aspirin (80% versus 93%, P = 0.006), clopidogrel (49% versus 82%, P \< 0.0001), statins (13% versus 61%, P \< 0.0001) and beta blockers (28% versus 62%, P \< 0.0001). Coronary angioplasty was less commonly utilized in those patients as well (12% versus 38%, P = 0.003), but the rates of coronary artery bypass graft (CABG) were similar. When separate analyses were done for STEMI and NSTEMI patients (also shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}), similar patterns were noted in both groups.

Using multivariate logistic regression analysis ([Table 3](#T3){ref-type="table"}), the significant multivariate predictors of mortality in the overall AMI population were: older age (\> 65 years), lower systolic blood pressure and CHF on admission, prior history of stroke or CABG and a lower ejection fraction. Age, CHF on admission and a lower EF continued to be multivariate predictors for both STEMI and NSTEMI subgroups. In addition, prior stroke was an added predictor in STEMI patients, and prior CABG was an added predictor in NSTEMI patients.

###### Multivariate Predictors of Mortality

                     Predictor              Adjusted OR (95% CI)   P value
  ------------------ ---------------------- ---------------------- ---------
  All AMI patients   Age (\> 65 years)      2.99 (1.22 - 7.36)     0.02
  SBP \< 100 mm Hg   2.75 (1.12 - 6.76)     0.03                   
  Stroke             4.28 (1.29 - 14.17)    0.02                   
  CABG               2.68 (1.15 - 6.23)     0.02                   
  Admission CHF      3.92 (1.62 - 9.49)     0.002                  
  Plavix             0.25 (0.10 - 0.49)     \< 0.0001              
  EF \< 35%          2.32 (1.05 - 5.14)     0.04                   
  STEMI              Age (\> 65 years)      3.56 (1.05 - 12.00)    0.041
  Admission CHF      5.11 (1.34 - 19.47)    0.017                  
  Stroke             10.43 (2.09 - 52.05)   0.004                  
  EF \< 35 %         3.31 (1.03 - 10.62)    0.044                  
  Non-STEMI          Age (\> 65 years)      3.97 (1.08 - 14.54)    0.038
  Admission CHF      2.49 (0.86 - 7.24)     0.093                  
  CABG               2.42 (0.91 - 6.42)     0.077                  
  EF \< 35 %         3.12 (1.13 - 8.66)     0.029                  

CHF: congestive heart failure; CABG: coronary artery bypass graft; EF: ejection fraction; SBP: systolic blood pressure.

Discussion {#s4}
==========

This is one of the few studies that analyzed the predictors of in-hospital mortality in a relatively large number of patients hospitalized with AMI in a tertiary referral university hospital in a developing country. The identified predictors were similar to those reported from large AMI registries in the USA and Europe. Older age has been a consistent predictor of mortality in multiple AMI studies. In a 20-year population study, Goldberg et al showed that the risk of death increased proportionally with age with patients older than 85 years of age having more than 10 times the mortality risk compared to patients ageing between 55 and 64 years \[[@R15]\]. Similar findings were reported by Rosengren et al from the EuroHeart survey \[[@R16]\]. Our findings are consistent with these studies where age was a significant predictor of in-hospital mortality in the overall AMI population as well as in each of the STEMI and NSTEMI subgroups. Multiple reasons have been proposed to explain this increased risk. Elderly people are expected to have more extensive coronary disease and yet they are less likely to receive the same intensive management as younger patients regarding revascularization procedures and anti-ischemic therapy \[[@R16]-[@R19]\]. Both the CRUSADE and EuroHeart studies showed that the revascularization rate decreased progressively as the patient's age increased \[[@R18]\].

Heart failure and low ejection fraction (\< 35%) were also shown to be consistent predictors of mortality in our overall AMI population as well as in both STEMI and NSTEMI subgroups. The ESC guidelines have underscored the importance of these two variables in the management of patients with AMI in view of their association with high risk \[[@R20]\]. Killip class was determined to be an important predictor of mortality for more than 50 years now \[[@R21]\]. The importance of heart failure on admission was further illustrated in a large nationwide USA study (NRMI-2) that enrolled around 170,000 patients with AMI in which it was associated with a five-fold increase in mortality \[[@R22]\]. Similarly, the GRACE registry showed that heart failure on admission was associated with four-fold increase in mortality \[[@R02]\].

Prior history of stroke was an important predictor of mortality in our study as well. This goes hand in hand with various studies that found that patients who survive an initial stroke are more prone to die in the future from cardiac events such as myocardial infarction \[[@R23], [@R24]\]. The CRUSADE registry that enrolled around 43,000 patients with AMI showed that stroke was a strong predictor of long-term morality \[[@R25]\].

Patients with prior history of CABG have also been shown in multiple studies to be at increased risk of death following an AMI \[[@R26], [@R27]\], similar to what we found in our study. Finally, we found that the lack of utilization of clopidogrel was a significant predictor of mortality. The protective effect of clopidogrel has now been established in multiple randomized trials in a wide spectrum of patients with acute coronary syndromes \[[@R28]-[@R30]\]. However, because of the retrospective nature of our study, it is difficult to determine whether the lack of prescribing clopidogrel leads to the increased mortality or it was simply a marker of a higher risk population.

Strengths and limitations {#s4a}
-------------------------

This is one of the few studies that analyzes the predictors of in-hospital mortality among patients with AMI in a developing country. In view of the scarcity of similar data from these countries, our report fills an important gap of knowledge in the global perspective on AMI. The important limitations of the study are that it is a single-center initiative and it is retrospective. This limits the extrapolation of findings to other countries. We hope that more resources will be invested in these countries to perform multicenter prospective surveys that can more accurately characterize the population of AMI patients.

Conclusions {#s4b}
-----------

This is one of the few studies that analyzes the predictors of in-hospital mortality among patients hospitalized with AMI in a large tertiary referral university hospital in the Middle East. The identified predictors are similar to what has been reported in large registries in the USA and Europe. These included older age, heart failure, prior stroke or CABG, and a lower ejection fraction. Large multicenter prospective studies are needed to further characterize the population of AMI patients in these countries.
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